Cargando…

Antibody response to pneumococcal and influenza vaccination in patients with rheumatoid arthritis receiving abatacept

BACKGROUND: Patients with rheumatoid arthritis (RA), including those treated with biologics, are at increased risk of some vaccine-preventable infections. We evaluated the antibody response to standard 23-valent pneumococcal polysaccharide vaccine (PPSV23) and the 2011–2012 trivalent seasonal influe...

Descripción completa

Detalles Bibliográficos
Autores principales:	Alten, Rieke, Bingham, Clifton O., Cohen, Stanley B., Curtis, Jeffrey R., Kelly, Sheila, Wong, Dennis, Genovese, Mark C.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2016
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4880815/ https://www.ncbi.nlm.nih.gov/pubmed/27229685 http://dx.doi.org/10.1186/s12891-016-1082-z

Ejemplares similares

Long-Term Safety of Subcutaneous Abatacept in Rheumatoid Arthritis: Integrated Analysis of Clinical Trial Data Representing More Than Four Years of Treatment
por: Alten, Rieke, et al.
Publicado: (2014)

Body mass index and clinical response to intravenous or subcutaneous abatacept in patients with rheumatoid arthritis
por: D’Agostino, Maria-Antonietta, et al.
Publicado: (2017)

Rituximab and abatacept but not tocilizumab impair antibody response to pneumococcal conjugate vaccine in patients with rheumatoid arthritis
por: Crnkic Kapetanovic, Meliha, et al.
Publicado: (2013)

The effect of tofacitinib on pneumococcal and influenza vaccine responses in rheumatoid arthritis
por: Winthrop, Kevin L, et al.
Publicado: (2016)

Abatacept in the treatment of rheumatoid arthritis
por: Buch, Maya H, et al.
Publicado: (2008)

Abatacept in the treatment of rheumatoid arthritis
por: Vital, Edward M, et al.
Publicado: (2006)

Abatacept treatment for rheumatoid arthritis
por: Schiff, Michael
Publicado: (2011)

Real-world predictors of 12–month intravenous abatacept retention in patients with rheumatoid arthritis in the ACTION observational study
por: Alten, Rieke, et al.
Publicado: (2017)

The Use of Abatacept for the Treatment of Felty Syndrome in Rheumatoid Arthritis
por: Chin, Rishika V, et al.
Publicado: (2023)

Subcutaneous abatacept for the treatment of rheumatoid arthritis
por: Schiff, Michael
Publicado: (2013)

Effect of abatacept on the immunogenicity of 23-valent pneumococcal polysaccharide vaccination (PPSV23) in rheumatoid arthritis patients
por: Migita, Kiyoshi, et al.
Publicado: (2015)

Comparative Effectiveness of Abatacept vs. Tofacitinib in Rheumatoid Arthritis Patients who are CCP+
por: Harrold, Leslie R., et al.
Publicado: (2023)

Subcutaneous abatacept for the treatment of rheumatoid arthritis in routine clinical practice in Germany, Austria, and Switzerland: 2-year retention and efficacy by treatment line and serostatus
por: Alten, Rieke, et al.
Publicado: (2023)

Impact of intravenous abatacept on synovitis, osteitis and structural damage in patients with rheumatoid arthritis and an inadequate response to methotrexate: the ASSET randomised controlled trial
por: Conaghan, Philip G, et al.
Publicado: (2013)

Immunogenicity of an adalimumab biosimilar, FKB327, and its reference product in patients with rheumatoid arthritis
por: Alten, Rieke, et al.
Publicado: (2020)

Abatacept: the evidence for its place in the treatment of rheumatoid arthritis
por: Köller, Marcus D.
Publicado: (2007)

Efficacy, safety, and tolerability of abatacept in the management of rheumatoid arthritis
por: Lutt, Joseph R
Publicado: (2009)

Evaluation of pneumococcal and tetanus vaccine responses in patients with rheumatoid arthritis receiving baricitinib: results from a long-term extension trial substudy
por: Winthrop, Kevin L., et al.
Publicado: (2019)

Sustained Remission and Outcomes with Abatacept plus Methotrexate Following Stepwise Dose De-escalation in Patients with Early Rheumatoid Arthritis
por: Emery, Paul, et al.
Publicado: (2023)

Retention of subcutaneous abatacept for the treatment of rheumatoid arthritis: real-world results from the ASCORE study: an international 2-year observational study
por: Alten, Rieke, et al.
Publicado: (2022)

Decreased use of glucocorticoids in biological-experienced patients with rheumatoid arthritis who initiated intravenous abatacept: results from the 2-year ACTION study
por: Alten, Rieke, et al.
Publicado: (2016)

Pneumococcal polysaccharide vaccination in rheumatoid arthritis patients receiving tacrolimus
por: Migita, Kiyoshi, et al.
Publicado: (2015)

Baseline autoantibodies preferentially impact abatacept efficacy in patients with rheumatoid arthritis who are biologic naïve: 6-month results from a real-world, international, prospective study
por: Alten, Rieke, et al.
Publicado: (2017)

Subcutaneous abatacept in rheumatoid arthritis: A real-life experience
por: Sarmiento-Monroy, Juan Camilo, et al.
Publicado: (2019)

Identification of molecules associated with response to abatacept in patients with rheumatoid arthritis
por: Yokoyama-Kokuryo, Waka, et al.
Publicado: (2020)

Efficacy and safety of abatacept in patients with rheumatoid arthritis with previous malignancy
por: Kunishita, Yosuke, et al.
Publicado: (2023)

The 6-month safety and efficacy of abatacept in patients with rheumatoid arthritis who underwent a washout after anti-tumour necrosis factor therapy or were directly switched to abatacept: the ARRIVE trial
por: Schiff, M, et al.
Publicado: (2009)

Pneumococcal polysaccharide vaccination in rheumatoid arthritis patients receiving tocilizumab therapy
por: Mori, Shunsuke, et al.
Publicado: (2013)

Malignancies in the rheumatoid arthritis abatacept clinical development programme: an epidemiological assessment
por: Simon, T A, et al.
Publicado: (2009)

Pneumocystis jirovecii Pneumonia in a Patient with Rheumatoid Arthritis Treated with Abatacept
por: Ospina, Fabio E., et al.
Publicado: (2014)

Squamous-cell carcinoma of the tongue following therapy of rheumatoid arthritis with abatacept
por: Deidda, Arianna, et al.
Publicado: (2014)

Postmarketing surveillance of the safety and effectiveness of abatacept in Japanese patients with rheumatoid arthritis
por: Harigai, Masayoshi, et al.
Publicado: (2016)

Reduced T-cell repertoire restrictions in abatacept-treated rheumatoid arthritis patients
por: Imberti, Luisa, et al.
Publicado: (2015)

Critical appraisal of efficacy and safety of abatacept in the treatment of refractory rheumatoid arthritis
por: Lundquist, Lisa M, et al.
Publicado: (2012)

Actual Persistence of Abatacept in Rheumatoid Arthritis: Results of the French-Ric Network
por: Salmon, Jean-Hugues, et al.
Publicado: (2020)

Comparing the effectiveness and safety of Abatacept and Tocilizumab in elderly patients with rheumatoid arthritis
por: Temmoku, Jumpei, et al.
Publicado: (2022)

Real-world effectiveness and safety of tofacitinib and abatacept in patients with rheumatoid arthritis
por: Hirose, Wataru, et al.
Publicado: (2022)

Long-term safety, immunogenicity and efficacy comparing FKB327 with the adalimumab reference product in patients with active rheumatoid arthritis: data from randomised double-blind and open-label extension studies
por: Genovese, Mark C, et al.
Publicado: (2020)

Opsonic and Antibody Responses to Pneumococcal Polysaccharide in Rheumatoid Arthritis Patients Receiving Golimumab Plus Methotrexate
por: Migita, Kiyoshi, et al.
Publicado: (2015)

Real-world effectiveness of abatacept for rheumatoid arthritis treatment in European and Canadian populations: a 6-month interim analysis of the 2-year, observational, prospective ACTION study
por: Nüßlein, Hubert G, et al.
Publicado: (2014)

Cannot write session to /tmp/vufind_sessions/sess_krsn6f9irvtnri5p91lmrj7ft1